AD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25

Transcription

1 A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475, 481, 506 actinic keratoses 5-fluorouracil 05 Actinomycin-D. See dactinomycin-d ACT regimen, 475 AC T regimen, 476, AC T 1 trastuzumab regimen, acute leukemias carboplatin and, 87 primary induction acute lymphoblastic leukemia (ALL) asparaginase and, 34 clofarabine, 112 daunorubicin and, 139 idarubicin 29 mercaptopurine 83 methotrexate 86 primary induction T-cell, 303 thioguanine and, 393 acute lymphocytic leukemia cytarabine and, 122 imatinib 37, 238 acute myelogenous leukemia (AML) cytarabine and, 122 daunorubicin and, 139 etoposide phosphate and, 190 hydroxyurea 22 idarubicin 29 mitoxantrone 99 thioguanine and, 393 acute promyelocytic leukemia (APL) arsenic trioxide, 30, 31 tretinoin and, 415 Adcetris. See brentuximab adjuvant treatment to local treatment modalities, 2 3 ADOC regimen, 581 ado-trastuzumab emtansine, 8 10, 487 AD regimen, 576 adrenal steroid inhibitor aminoglutethimide, adrenocortical cancer mitotane 96 adrenolytic agent mitotane, Adriamycin. See doxorubicin Afinitor. See everolimus AG See axitinib AIDA regimen, 525 a-interferon. See interferon-a AI regimen, 577 albumin-bound paclitaxel, alcohol lomustine 71 nilutamide and, 309 procarbazine and, 353 thalidomide and, 389 aldesleukin, alemtuzumab, 17 19, , 457 Alimta. See pemetrexed Alkeran. See melphalan alkylating agents bendamustine, busulfan, carmustine, chlorambucil, , dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, streptozocin, thiotepa, ALL. See acute lymphoblastic leukemia (ALL) allopurinol ifosfamide 34 mercaptopurine 83 All- trans -retinoic acid. See tretinoin Aloxi. See palonosetron altretamine, , 457 aluminum hydroxide, capecitabine and, 83 Amethopterin. See methotrexate amifostine cisplatin and, amino-9-b-D-arabinofu- ranosyl-6-methoxy- 9H-purine. See nelarabine aminoglutethimide, , 457 megestrol acetate 77 aminoglycosides cisplatin and, 105 amiodarone AML. See acute myelogenous leukemia (AML)

2 AMN107. See nilotinib amphotericin B carmustine and, 94 cisplatin and, 105 amputees (adult), body surface area of, 450 amsacrine dialysis guidelines, anal cancer fluorouracil 05 neoadjuvant anaplastic astrocytomas adjuvant and, 3 temozolomide and, 383 anaplastic large cell lymphoma brentuximab and, 68 anastrozole, 26 28, 480, 486 adjuvant treatment to local treatment modalities, 3 antacids vismodegib and, 439 anthracyclines trastuzumab and, 412 antiandrogen bicalutamide, enzalutamide, flutamide, nilutamide, anti-angiogenic agent lenalidomide, pomalidomide, thalidomide, antibody-drug conjugate ado-trastuzumab emtansine, 8 10 anticoagulants antidiabetic agents procarbazine and, 353 anti-egfr antibody cetuximab, panitumumab, antiemetic agents aprepitant, , dexamethasone, , 632, 633 diphenhydramine, dolasetron, , 632, 633, 635 dronabinol, , 635 granisetron, 106, lorazepam, metoclopramide, , 632, 634, 635 nabilone, , 635 ondansetron, 106, , 632, 633, overview, 601 palonosetron, , 633, 634 prochlorperazine, , 632, 635 antiestrogen tamoxifen, toremifene, Anti-HER-2-antibody. See pertuzumab; trastuzumab antihistamines diphenhydramine, procarbazine and, 353 antimetabolite azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, pralatrexate, thioguanine, antimicrotubule agent albumin-bound paclitaxel, cabazitaxel, docetaxel, eribulin, estramustine, ixabepilone, paclitaxel, vinblastine, vincristine, vinorelbine, antineoplastic agent decitabine, antithymocyte globulin (ATG) 1 cyclosporine regimen, 563 antitumor antibiotic bleomycin, dactinomycin-d, daunorubicin, daunorubicin liposome, doxorubicin, doxorubicin liposome, epirubicin, mitomycin-c, mitoxantrone, antitumor antibiotics idarubicin, anti-vegf antibody bevacizumab, ziv-aflibercept, Anzemet. See dolasetron AP See ponatinib APC8015. See sipuleucel-t APL. See acute promyelocytic leukemia (APL) AP regimen, 506 aprepitant, , Ara-C. See cytarabine area under the curve (AUC), 449 Arimidex. See anastrozole Aromasin. See exemestane aromatase inhibitor letrozole, Arranon. See nelarabine Index 641

3 642 Index arsenic trioxide (As 2 O 3 ), 29 32, 527 Arzerra. See ofatumumab asparaginase, cytarabine and, 124 methotrexate 88 vincristine and, 432 aspirin methotrexate 87 pemetrexed and, 336 pralatrexate and, 350 astemizole astrocytomas, 94 anaplastic, 3, 383 atazanavir A T C, 478 Ativan. See lorazepam ATRA. See tretinoin ATRA regimen, 527 AT regimen, 481 AUC. See area under the curve (AUC) Avastin. See bevacizumab axitinib, azacitidine, 41 43, 527, Aza-2 -deoxycytidine. See decitabine azidothymidine (AZT) hydroxyurea 22 azithromycin vismodegib and, 439 B barbiturates mitotane 96 thalidomide and, 389 basal cell carcinoma regimens, fluorouracil 05 vismodegib and, 439 BAY See sorafenib BAY See regorafenib B-cell chronic lymphocytic leukemia (B-CLL) alemtuzumab and, 17 BCNU. See carmustine BCNU regimen, BEACOPP regimen, 542 Benadryl. See diphenhydramine bendamustine, 44 46, 530, 552 benzodiazepine lorazepam, BEP regimen, 568, 579 bepridil bevacizumab, 47 50, 475, 519 bexarotene, Bexxar. See tositumomab bicalutamide, 54 55, 220 BIC regimen, 492 biliary tract cancer, regimens, biologic response modifier agent ado-trastuzumab emtansine, 8 10 aldesleukin, alemtuzumab, bevacizumab, brentuximab, cetuximab, denileukin difitox, ibritumomab, interferon-a, ipilimumab, lenalidomide, ofatumumab, panitumumab, pertuzumab, pomalidomide, rituximab, sipuleucel-t, thalidomide, tositumomab, trastuzumab, ziv-aflibercept, BIP regimen, 491 Bischloroethylnitrosourea. See carmustine bladder cancer carboplatin and, cisplatin and, 104 docetaxel and, 154 gemcitabine 17 ifosfamide 33 methotrexate 86 mitomycin-c and, 292 neoadjuvant paclitaxel and, 323 thiotepa and, 396 Blenoxane. See bleomycin bleomycin, brentuximab and, 68 cisplatin and, 105 BMP regimen, 561 BMPT regimen, 561 BMS See ixabepilone BMS See dasatinib body surface area (BSA) of amputees (adult), 450 dosage determination from, bone sarcoma

4 bortezomib, 60 63, 553, 562 doxorubicin liposome and, 164 Bosulif. See bosutinib bosutinib, 64 66, brain stem glioma, 94 brain tumor carmustine and, lomustine 71 procarbazine and, 353 breast cancer adjuvant treatment to local treatment modalities, 3 ado-trastuzumab emtansine for, 9 albumin-bound paclitaxel for, 12 aminoglutethimide 3 anastrozole 7 capecitabine and, docetaxel and, 154, 155 epirubicin and, 171 etoposide and, 185 exemestane and, fluorouracil 05 fulvestrant 11 gemcitabine 16 ixabepilone 55 lapatinib 58 letrozole 65 megestrol acetate 77 melphalan 80 methotrexate 86 mitomycin-c 92 mitoxantrone 99 neoadjuvant optimal duration of drug administration, 4 paclitaxel and, 323 tamoxifen and, 379 thiotepa and, 396 toremifene and, 402 trastuzumab and, 412 vinorelbine and, 435 brentuximab, 67 69, 553 bleomycin and, 58 bretylium BSA. See body surface area (BSA) bupropion Burkitt s lymphoma primary induction buserelin busulfan, 70 72, 531 Busulfex. See busulfan BV regimen, 519 C cabazitaxel, cabozantinib, CAE regimen, CAF regimen, 477, 481 calcium channel blockers Calvert formula, for carboplatin dose, 87 Campath. See alemtuzumab Camptosar. See irinotecan cancer of unknown primary, cannabinoid dronabinol, nabilone, capecitabine, 80 85, 487, 496, 504, 519, 571 CAP regimen, 472, 506, 557, 580 Caprelsa. See vandetanib carbamazepine cabozantinib and, 78 dasatinib and, 136 erlotinib and, 178 everolimus and, 192 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 toremifene and, 402 carboplatin, albumin-bound paclitaxel for non small cell lung cancer, 12 area under the curve, 449 paclitaxel and, 324 carcinoid tumors streptozocin and, 372 carcinomatous meningitis methotrexate 86 carfilzomib, 90 92, 562 Index 643

5 644 Index carmustine, , 457 Casodex. See bicalutamide CAV alternating with IE regimen, 578 CAV regimen, 539 CBDCA. See carboplatin CC See lenalidomide CCI-779. See temsirolimus CCNU. See lomustine CC regimen, CdA. See cladribine CDDP. See cisplatin CEF regimen, 481 CEL. See chronic eosinophilic leukemia (CEL) cephalosporins methotrexate 87 pralatrexate and, 350 Cerubidine. See daunorubicin cervical cancer ifosfamide 33 mitomycin-c 92 topotecan and, 399 Cesamet. See nabilone cetuximab, 96 99, , 518 CF regimen, 511, 527 adjuvant treatment to local treatment modalities, 2 3 clinical efficacy, obstacles to, 1 combination, 3 4 guidelines (See guidelines, ) neoadjuvant, 2 overview, 1 primary induction, 2 principles of, 1 4 salvage, 468 drugs ado-trastuzumab emtansine, 8 10 albumin-bound paclitaxel, altretamine, arsenic trioxide, asparaginase, axitinib, azacitidine, bendamustine, bleomycin, bortezomib, bosutinib, busulfan, cabazitaxel, cabozantinib, capecitabine, carboplatin, carfilzomib, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, crizotinib, , cytarabine and, dabrafenib, dacarbazine, dactinomycin-d, dasatinib, daunorubicin, daunorubicin liposome, docetaxel, doxorubicin, doxorubicin liposome, emetogenic potential of, epirubicin, eribulin, erlotinib, estramustine, etoposide, etoposide phosphate, everolimus, floxuridine, fludarabine, fluorouracil, gefitinib, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, ironotecan, ixabepilone, lapatinib, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin-c, mitotane, mitoxantrone, nelarabine, nilotinib, omacetaxine mepesuccinate, oxaliplatin, paclitaxel, pazopanib, pemetrexed, ponatinib, pralatrexate, procarbazine, regorafenib, romidepsin, sorafenib, streptozocin, sunitinib, temozolomide, temsirolimus, thioguanine, thiotepa, topotecan, trametinib, vandetanib, vemurafenib, vinblastine, vincristine, vinorelbine, vismodegib, vorinostat, See also specific drugs acute lymphocytic leukemia, acute myelogenous leukemia, anal cancer, basal cell carcinoma, 469 biliary tract cancer,

6 bladder cancer, brain tumor, breast cancer, Burkitt s lymphoma, cancer of unknown primary, carcinoid tumors, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hairy cell leukemia, 531 head and neck cancer, hepatocellular cancer, Hodgkin s lymphoma, Kaposi s sarcoma, lymphoma, malignant melanoma, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, non-hodgkin s lymphoma, non-small cell lung cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, primary CNS lymphoma, prostate cancer, renal cell cancer, small cell lung cancer, soft tissue sarcoma, testicular cancer, thymoma, thyroid cancer, chlorambucil, , Chlorodeoxyadenosine. See cladribine chloroquine chlorpromazine thalidomide and, 389 CHOP regimen, 544, 545 CHOP 1 rituximab regimen, 546 choriocarcinoma primary induction chronic eosinophilic leukemia (CEL) imatinib 38 chronic leukemias chronic lymphocytic leukemia (CLL) bendamustine and, chlorambucil and, 101 cladribine and, 109 fludarabine 02 ofatumumab and, 312 chronic myelogenous leukemia (CML) busulfan and, 71 regimens, cytarabine and, 123 dasatinib and, 136 hydroxyurea 22 idarubicin 29 imatinib 37 interferon-a 42 nilotinib and, 306 omacetaxine mepesuccinate and, 316 thioguanine and, 393 chronic myelomonocytic leukemia azacitidine and, 42 cimetidine carmustine and, 94 epirubicin and, 171 ifosfamide 34 lomustine 71 melphalan 80 tretinoin and, 415 ciprofloxacin Cis-diamminedichloroplatinum,. See cisplatin cisplatin, , 519 bleomycin and, 57 cytarabine and, 123 fludarabine 02 gemcitabine 17 granisetron and, 614 ifosfamide 34 paclitaxel and, 324 vincristine and, 432 vinorelbine and, 435 cladribine, , 526, 529, , 458 clarithromycin cabozantinib and, 78 dasatinib and, 136 erlotinib and, 179 everolimus and, 193 exemestane and, 196 gefitinib 13 Index 645

7 646 Index clarithromycin Cont. imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 vismodegib and, 439 CLL. See chronic lymphocytic leukemia (CLL) clofarabine, , 524, 527 Clolar. See clofarabine clopidogrel (plavix) letrozole 65 CMF regimen, 482 CML. See chronic myelogenous leukemia (CML) CMV regimen, 471 CNOP regimen, 544, 546 CNS lymphoma, primary methotrexate 86 CODOX-M regimen, 550 colon cancer capecitabine and, 82 oxaliplatin and, 319 colorectal cancer adjuvant treatment to local treatment modalities, 3 bevacizumab and, 48 capecitabine and, floxuridine and, fluorouracil 05 ironotecan and, 250, 251 optimal duration of drug administration, 4 oxaliplatin and, 319 panitumumab and, 328 ziv-aflibercept and, 445 combination, 3 4 Cometriq. See cabozantinib Compazine. See prochlorperazine Cosmegen. See dactinomycin-d coumadin mercaptopurine 83 CP regimen, 527, 564 CPT-11. See irinotecan creatinine clearance, determination of, crizotinib, Crockcroft-Gault formula, for creatinine clearance, CTCL. See cutaneous T-cell lymphoma (CTCL) CT regimen, 565 CTX. See cutaneous T-cell lymphoma (CTCL) bexarotene and, 51, 52 denileukin difitox and, 150 fludarabine 02 interferon-a 42 mechlorethamine 74 procarbazine and, 353 vorinostat and, 442 CVP regimen, 527, 543, and busulfan in stem cell transplant, 71 doxorubicin and, 160 epirubicin and, 171 fludarabine 02 mitotane 96 paclitaxel and, 324 rituximab and, 360 tamoxifen and, 379 cyclosporine docetaxel and, 155 melphalan 80 tretinoin and, 415 Cytadren. See aminoglutethimide cytarabine, , 526 fludarabine 02 cytokines aldesleukin, cytarabine and, 124 Cytosine arabinoside. See cytarabine Cytoxan. See CYVADIC regimen, 577 D DAB389. See denileukin difitox dabrafenib, dacarbazine, Dacogen. See decitabine dactinomycin dactinomycin-d, dasatinib, , 524, Daunomycin. See daunorubicin daunorubicin, , 520 daunorubicin liposome, DaunoXome. See daunorubicin liposome DCF regimen, 511

8 DCIS. See ductal carcinoma in situ (DCIS) Decadron. See dexamethasone decitabine, , 527, 562 degarelix, degramont regimen, 496, Demethoxydaunorubicin. See idarubicin denileukin difitox, depsipeptide. See romidepsin dexamethasone, 561, , 632, 633 daunorubicin and, 139 everolimus and, 192 dexrazoxane daunorubicin and, 139 doxorubicin and, 160 dextromethorphan DHAP (salvage regimen), 548 DH FEC regimen, 479 Diaminocyclohexane platinum. See oxaliplatin DIC. See dacarbazine dideoxycytidine (ddc) hydroxyurea 22 dideoxyinosine (ddi) hydroxyurea 22 differentiating agents arsenic trioxide, bexarotene, tretinoin, digoxin carmustine and, 94 cytarabine and, 123 vincristine and, 432 dilantin dasatinib and, 136 erlotinib and, 178 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 diltiazem everolimus and, 193 tretinoin and, 415 diphenhydramine, disopyramide docetaxel, , 487, 493, 513, 517, 520 and abiraterone acetate for prostate cancer, 6 capecitabine and, 82 pertuzumab and, 339 docetaxel AC regimen, 478 dofetilide dolasetron, , 632, 633, 635 Douillard regimen, 497 Doxil. See doxorubicin liposome doxorubicin, , 487, 488, 507, 519, paclitaxel and, 324 doxorubicin liposome, dronabinol, , 635 droperidol DTIC 1 BCNU 1 cisplatin regimen, 555 DTIC-Dome. See dacarbazine ductal carcinoma in situ (DCIS) tamoxifen and, 379 duloxetine DVD regimen, 560 E ECF regimen, 509, 511 ECOG performance scale, 448 ECOG regimen, 569 EC regimen, 539 ECX regimen, 510, 512 Efudex. Se e 5-fluorouracil Ellence. See epirubicin Eloxatin. See oxaliplatin Elspar. See asparaginase embryonal rhabdomyosarcoma primary induction Emcyt. See estramustine Emend. See aprepitant endometrial cancer carboplatin and, megestrol acetate 77 tamoxifen and, 379 ENL. See erythema nodosum leprosum (ENL) enzalutamide, enzymes asparaginase, EOF regimen, 510, 511 EORTC regimen, 467 EOX regimen, 510, 512 EP 1 docetaxel regimen, 536 ependymoma, 94 4 Epi-doxorubicin. See epirubicin epipodophyllotoxin etoposide, etoposide phosphate, Index 647

9 648 Index epirubicin, EPOCH regimen, 546 EPOCH 1 rituximab regimen, 547 epothilone ixabepilone, EP regimen, 488, 536, 538, 579 Erbitux. See cetuximab eribulin, , 488 Erivedge. See vismodegib erlotinib, erythema nodosum leprosum (ENL) thalidomide and, 389 erythromycin bexarotene and, 52 cabozantinib and, 78 dasatinib and, 136 docetaxel and, 155 erlotinib and, 179 everolimus and, 193 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 toremifene and, 402 tretinoin and, 415 vismodegib and, 439 ESHAP (salvage regimen), 548 esophageal cancer regimens, cisplatin and, fluorouracil 05 neoadjuvant paclitaxel and, 323 Estracyte. See estramustine estramustine, estrogen receptor antagonist fulvestrant, Etopophos. See etoposide phosphate etoposide, , 520 cisplatin and, 105 etoposide phosphate, Eulexin. See flutamide EVAP regimen, 542 EVA regimen, 541 everolimus, , 490 Ewing s sarcoma dactinomycin-d, 133 ifosfamide 33 exemestane, , 486 F Fareston. See toremifene Faslodex. See fulvestrant FC regimen, 544 FCR regimen, 527, 544 FEC docetaxel regimen, 477 FEC regimen, 477 FEC-50 regimen, 483 FEC-75 regimen, 483 FEC-100 regimen, 483 Femara. See letrozole FFD French regimen, 508 filgrastim vincristine and, 432 Firmagon. See degarelix FLAG regimen, 526 FLO regimen, 513 FLOX regimen, 496 floxuridine, , , 458 fluconazole everolimus and, 193 ixabepilone 55 Fludara. See fludarabine fludarabine, , 529, 552 alemtuzumab, 17 cytarabine and, , 458 rituximab and, Fluoro-ara-AMP. See fludarabine 5-fluorocytosine cytarabine and, Fluoro-2 -deoxyuridine. See floxuridine 5-fluorouracil, , 505 colorectal cancer and irinotecan, , 458 epirubicin and, 171 hydroxyurea 22 methotrexate 87 pemetrexed and, 336 fluoxetine flutamide, , , 459 FND regimen, 544 FOLFIRI 1 bevacizumab regimen, 503 FOLFIRI 1 cetuximab regimen, 502 FOLFIRINOX regimen, 570 FOLFIRI 1 panitumumab regimen, 503 FOLFIRI regimen, 497 FOLFIRI 1 ziv-aflibercept regimen,

10 FOLFOX 4 1 bevacizumab regimen, 501 FOLFOX 1 cetuximab 4 regimen, 502 FOLFOX6 1 cetuximab regimen, FOLFOXIRI regimen, 499 FOLFOX 4 1 panitumumab regimen, 503 FOLFOX regimen, 495, 4 498, 518 FOLFOX regimen, FOLFOX 7 regimen, 498 folic acid supplements methotrexate 87 Folotyn. See pralatrexate FP regimen, 527 FP 1 trastuzumab regimen, 513 FR regimen, FU. See 5-fluorouracil FUDR. See floxuridine fulvestrant, , 486 furosemide cisplatin and, 105 G gastric cancer adjuvant treatment to local treatment modalities, docetaxel and, 154, 155 epirubicin and, 171 etoposide and, fluorouracil 05 mitomycin-c 92 trastuzumab and, 412 gastroesophageal cancer oxaliplatin and, 319 trastuzumab and, 412 gastrointestinal (GI) adenocarcinoma floxuridine and, 198 gastrointestinal stromal tumor (GIST) adjuvant treatment to local treatment modalities, imatinib 37, 238 optimal duration of drug administration, 4 GBM. See glioblastoma multiformae (GBM) GCB regimen, 534 GCP regimen, 489 gefitinib, , 459 GEM-CAP regimen, 569 gemcitabine, , 472, 487, 493, , 459 gemfibrozil bexarotene and, 52 GEMOX regimen, 518 gemtuzumab, 527 Gemzar. See gemcitabine gentamicin cytarabine and, 123 German AIO regimen, German schedule, low dose regimen, 500 germ cell cancer bleomycin and, 57 carboplatin and, 87 dactinomycin-d, 133 etoposide and, 185 etoposide phosphate and, 189 ifosfamide 33 ovarian, 568 primary induction gestational trophoblastic disease dactinomycin-d, 133 methotrexate 86 GITSG regimen, 568 Gleevec. See imatinib Gliadel, 94. See also carmustine glioblastoma, bevacizumab and, 48 glioblastoma multiformae (GBM) carmustine and, 94 temozolomide and, 383 glucocorticoid steroid dexamethasone, GnRH antagonist degarelix, goserelin, , 459 granisetron, , cisplatin and, 106 grapefruit juice grepafloxacin GTX regimen, 569 guidelines, area under the curve, 449 body surface area in adult amputees, 450 creatinine clearance, dialysis of drugs, drug dose determination of, hepatic function and, renal function and, patient factors, 447 performance scales, 448 GVD regimen, 543 GW See lapatinib H hairy cell leukemia regimens, 531 cladribine and, 109 interferon-a 42 Halaven. See eribulin halofantrine haloperidol H2-blockers Index 649

11 650 Index HCC. See hepatocellular cancer (HCC) HDAC inhibitor. See histone deacetylase (HDAC) inhibitor head and neck cancer bleomycin and, 57 carboplatin and, 87 cetuximab and, cisplatin and, 104, 105 docetaxel and, 154, fluorouracil 05 hydroxyurea 22 ifosfamide 33 methotrexate 86 mitomycin-c 92 paclitaxel and, 323 hemangioma interferon-a 42 heparin dacarbazine and, 130 daunorubicin and, 139 epirubicin and, 171 idarubicin 29 mitoxantrone 99 hepatic function, and dosage, hepatocellular cancer (HCC) regimens, hepatoma 5-fluorouracil 05 Herceptin. See trastuzumab Herskovic regimen, Hexalen. See altretamine Hexamethylmelamine. See altretamine histone deacetylase (HDAC) inhibitor romidepsin, vorinostat, HMM. See altretamine Hodgkin s lymphoma bleomycin and, 57 brentuximab and, 68 carmustine and, chlorambucil and, 101 dacarbazine and, 130 etoposide and, 185 gemcitabine 17 ifosfamide 33 lomustine 71 mechlorethamine 74 primary induction procarbazine and, 353 thiotepa and, 396 Hopkins/Yale regimen, 508 hormonal agents abiraterone acetate, 5 7 albumin-bound paclitaxel, aminoglutethimide, anastrozole, bicalutamide, degarelix, enzalutamide, exemestane, flutamide, fulvestrant, goserelin, letrozole, leuprolide, megestrol acetate, nilutamide, tamoxifen, toremifene, H2-receptor inhibitors vismodegib and, HT3 receptor antagonist dolasetron, granisetron, ondansetron, palonosetron, HuMax-CD20. See ofatumumab Hycamtin. See topotecan Hydrea. See hydroxyurea hydrocortisone dacarbazine and, 130 Hydroxydaunorubicin. See doxorubicin hydroxyurea, , 531 cytarabine and, , 459 Hyper-CVAD/MTX-Ara-C regimen, Hyper-CVAD regimen, 523 hypereosinophilic syndrome (HES) imatinib 37, 238 hypomethylating agents azacitidine, decitabine, I ibritumomab, ibritumomab tiuxetan regimen, 552 ibutilide IBW. See ideal body weight (IBW) ICE (salvage regimen), Iclusig. See ponatinib Idamycin. See idarubicin idarubicin, , 459 ideal body weight (IBW), IDEC-Y2B8. See ibritumomab Ifex. See ifosfamide IFL Saltz regimen, IFN-a. See interferon-a IFN 1 DTIC regimen, 555 ifosfamide, cisplatin and, , 459 IL-2. See aldesleukin imatinib, , , 524, 530, , 459

12 Imidazole Carboxamide. See dacarbazine immunomodulatory agent thalidomide, immunomodulatory analog of thalidomide lenalidomide, pomalidomide, immunotherapy aldesleukin, denileukin difitox, interferon-a, sipuleucel-t, indinavir Inlyta. See axitinib interferon-a, , , 459 Interferon-a2a. See interferon- a interleukin-2 453, 459 Intron A. See interferon- a ionizing radiation cytarabine and, 123 IPB regimen, 512 ipilimumab, IP regimen, 512 Iressa. See gefitinib irinotecan, , 475, 493 colorectal cancer and cetuximab, , 459 IROX regimen, 500 Isophosphamide. See ifosfamide isotretinoin 453, 459 Istodax. See romidepsin ITP regimen, 470 itraconazole bexarotene and, 52 busulfan and, 71 cabozantinib and, 78 dasatinib and, 136 everolimus and, 193 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 IVAC regimen, 550 ixabepilone, , , 459 Ixempra. See ixabepilone J Jevtana. See cabazitaxel K Kadcyla. See ado-trastuzumab emtansine Kaposi s sarcoma regimens, daunorubicin liposome and, 143 doxorubicin liposome and, 164 interferon-a 42 paclitaxel and, 323 Karnofsky performance scale, 448 ketoconazole bexarotene and, 52 bortezomib and, 61 cabozantinib and, 78 dasatinib and, 136 docetaxel and, 155 erlotinib and, 179 everolimus and, 193 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 toremifene and, 402 tretinoin and, 415 Kyprolis. See carfilzomib Kytril and Sancuso Transdermal Patch. See granisetron L lansoprazole lapatinib, dialysis guidelines, , 459 Larson regimen, laryngeal cancer neoadjuvant L-Asparaginase. See asparaginase Index 651

13 652 Index lenalidomide, , 530, 553, , 459 leptomeningeal carcinomatosis cytarabine and, 123 letrozole, , 480, 486 adjuvant treatment to local treatment modalities, 3 leucovorin capecitabine and, 83 floxuridine and, fluorouracil 06 methotrexate 87 pemetrexed and, 336 pralatrexate and, 350 leukemia acute lymphoblastic, 2, 34, 112 acute promyelocytic, 30, 31 B-CLL, 17 chronic lymphocytic ( See chronic lymphocytic leukemia (CLL)) chronic myelomonocytic, 42 hairy cell, 109 T-cell prolymphocytic, 18 Leukeran. See chlorambucil leuprolide, , 459 Leustatin. See cladribine levodopa procarbazine and, 353 LHRH agonist goserelin, leuprolide, lidocaine dacarbazine and, 130 Linker regimen, lomustine, , 459 lorazepam, L-PAM. See melphalan Lupron. See leuprolide LV 5 FU 2 1 mitomycin-c regimen, 501 LY See pemetrexed lymphoma anaplastic large cell, 68 Burkitt s, etoposide and, 185 Hodgkin s ( See Hodgkin s lymphoma) mantle cell, 61 non-hodgkin s (See non-hodgkin s lymphoma) peripheral T-cell, 350 primary CNS ( See CNS lymphoma, primary) T-cell lymphoblastic, 303 Lysodren. See mitotane M MACOP-B, 547 MAGIC Trial for esophageal cancer, 508 magnesium hydroxide, capecitabine and, 83 Magrath Protocol, MAID regimen, 577 malignant melanoma. See melanoma, malignant mantle cell lymphoma bortezomib and, 61 lenalidomide 61 Marinol. See dronabinol Matulane. See procarbazine Mayo Clinic schedule, 495, 500 m-bacod, MCV regimen, 472 MDS. See myelodysplastic syndromes (MDS) mechlorethamine, , 459 medulloblastoma, 94 Megace. See megestrol acetate megestrol acetate, , 459 Mekinist. See trametinib melanoma, malignant aldesleukin and, 15 regimens, dacarbazine and, 130 interferon-a 42 ipilimumab 45 temozolomide and, 383 trametinib and, 409 melphalan, , , 459 meningeal leukemia methotrexate 86 meperidine procarbazine and, mercaptopurine, , 459 doxorubicin and, 160 mesna cisplatin and, 105 mesoridazine mesothelioma, malignant regimens, pemetrexed and, 335 methadone methotrexate, , 518, 554 asparaginase and, 34 cisplatin and, 105 cytarabine and, , fluorouracil 06 vincristine and, 432

14 metoclopramide, , 632, 634, 635 mfolfox 7 regimen, 495, 498 MINE (salvage regimen), 549 Mini-BEAM regimen, 542 Mitomycin. See mitomycin-c mitomycin-c, , doxorubicin and, 160 vinorelbine and, 435 mitotane, , 460 mitoxantrone, , 460 fludarabine 02 monoclonal antibody alemtuzumab, bevacizumab, brentuximab, cetuximab, ibritumomab, ipilimumab, ofatumumab, panitumumab, pertuzumab, rituximab, tositumomab, trastuzumab, ziv-aflibercept, MOPP/ABVD hybrid regimen, 541 MOPP regimen, motion sickness diphenhydramine and, 607 moxifloxacin 6-MP. See 6-mercaptopurine MPL regimen, 559 MP regimen, 558 MPT regimen, 559 MTX. See methotrexate multiple myeloma bortezomib and, 61 carfilzomib and, 91 carmustine and, 94 regimens, doxorubicin liposome and, 164 interferon-a 42 lenalidomide 61 melphalan 80 pomalidomide and, 342 thalidomide and, 389 Mustargen. See mechlorethamine Mutamycin. See mitomycin-c MVAC regimen, 471 myelodysplastic syndromes (MDS) azacitidine and, decitabine and, 146 idarubicin 29 imatinib 37, 238 lenalidomide 61 thalidomide and, 389 myeloproliferative disease (MPD) imatinib 37, 238 myelosuppressive drugs carboplatin and, 87 thiotepa and, 396 Myleran. See busulfan N nabilone, , 635 natural product arsenic trioxide, Navelbine. See vinorelbine nefazodone nelarabine, , , 460 nelfinavir neoadjuvant, 2 nephrotoxic agents streptozocin and, 372 neuroblastoma dacarbazine and, 130 Nexavar. See sorafenib Nilandron. See nilutamide nilotinib, , 514, 524, nilutamide, 220, , 460 Nitrogen mustard. See mechlorethamine N-Methylhydrazine. See procarbazine Nolvadex. See tamoxifen nonclassic alkylating agent altretamine, procarbazine, temozolomide, non-hodgkin s lymphoma bendamustine and, 45 bleomycin and, 57 carmustine and, chlorambucil and, 101 cisplatin and, 104 cladribine and, 109 Index 653

15 654 Index non-hodgkin s lymphoma Cont. cytarabine and, 123 etoposide and, 185 fludarabine 02 gemcitabine 17 ibritumomab 25 ifosfamide 33 interferon-a 42 lomustine 71 mechlorethamine 74 methotrexate 86 mitoxantrone 99 ofatumumab and, 312 primary induction procarbazine and, 353 rituximab and, 360 thiotepa and, 396 tositumomab and, 405 non-small cell lung cancer (NSCLC) adjuvant treatment to local treatment modalities, 3 albumin-bound paclitaxel for, 12 bevacizumab and, 48, 49 carboplatin and, 87 regimens, cisplatin and, 104, 105 docetaxel and, 154, 155 erlotinib and, 178 etoposide and, 185 etoposide phosphate and, 189 gefitinib 13 gemcitabine and, 216, 217 ifosfamide 33 ironotecan 51 mitomycin-c 92 neoadjuvant paclitaxel and, 323 pemetrexed and, 335 vinorelbine and, 435 nonsteroidal antiinflammatory drugs (NSAIDs) pemetrexed and, 336 pralatrexate and, 350 nonsteroidal aromatase inhibitor anastrozole, nontaxane eribulin, Novantrone. See mitoxantrone NSAIDs. See nonsteroidal anti-inflammatory drugs (NSAIDs) O octreotide, 490 ofatumumab, , , 460 omacetaxine mepesuccinate, Oncovin. See vincristine ondansetron, , 632, 633, cisplatin and, 106 Ontak. See denileukin difitox OSI-774. See erlotinib osteogenic sarcoma adjuvant treatment to local treatment modalities, ifosfamide 33 methotrexate 86 neoadjuvant ovarian cancer altretamine 1 carboplatin and, cisplatin and, 104 and, 118 docetaxel and, 154 doxorubicin liposome and, 164 etoposide and, fluorouracil 05 gemcitabine 16 hydroxyurea 22 melphalan 80 paclitaxel and, 323 thiotepa and, 396 topotecan and, 399 vinorelbine and, 435 oxaliplatin, capecitabine and, , 460 oxygen, bleomycin and, 57 P paclitaxel, , 473, 487, 493, 507, 510, , 520 albumin-bound, carboplatin and, 88 cisplatin and, 105 dialysis guidelines, , 460 vincristine and, 432 palonosetron, , 633, 634 pancreatic cancer erlotinib and, fluorouracil 05 gemcitabine 16, 217 mitomycin-c 92 oxaliplatin and, 319 streptozocin and, 372 pancreatic neuroendocrine tumors (PNET) panitumumab, , , 460 Paraplatin. See carboplatin Parkinsonism diphenhydramine and, 607

16 paroxetine pazopanib, , 460 PCB regimen, 534 PCE regimen, 488 PCR regimen, 527 PCV regimen, 473, 474 PD regimen, 560 PEB regimen, 57, 488, pegasparaginase 455, 460 Peginterferon-a2b. See interferon- a pemetrexed, , 473, , 460 penicillins methotrexate 87 pralatrexate and, 350 pentamidine pentostatin, 530 performance scales, 448 peripheral T-cell lymphoma (PTCL) pralatrexate and, 350 Perjeta. See pertuzumab perphenazine pertuzumab, , 460 PF 1 cetuximab regimen, 516 PF-larynx preservation, 517 PF regimen, 516 P-glycoprotein (Pgp) inhibitors nilotinib and, 306 vismodegib and, 439 phenobarbital bexarotene and, 52 busulfan and, 71 cabozantinib and, 78 chlorambucil and, 101 dacarbazine and, 130 dasatinib and, 136 doxorubicin and, 160 erlotinib and, 178 everolimus and, 192 exemestane and, 196 gefitinib 13 ifosfamide 33 imatinib 38 interferon-a 42 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 paclitaxel and, 324 temsirolimus and, 386 toremifene and, 402 tretinoin and, 415 phenothiazine prochlorperazine, Phenylalanine mustard. See melphalan phenytoin bexarotene and, 52 busulfan and, 71 cabozantinib and, 78 capecitabine and, 83 carmustine and, 94 chlorambucil and, 101 cisplatin and, 105 dacarbazine and, 130 doxorubicin and, 160 ifosfamide 33 interferon-a 42 methotrexate 87 mitotane 96 paclitaxel and, 324 streptozocin and, 372 temsirolimus and, 386 toremifene and, 402 vinorelbine and, 435 pimozide Platinol. See cisplatin platinum analogs carboplatin, cisplatin, oxaliplatin, platinum-based erlotinib and, 179 PLX4032. See vemurafenib PNET. See pancreatic neuroendocrine tumors (PNET) polycythemia vera hydroxyurea 22 melphalan 80 pomalidomide, , 460 Pomalyst. See pomalidomide ponatinib, , , 460 PONV. See postoperative nausea and vomiting (PONV) posaconazole Index 655

17 656 Index postoperative nausea and vomiting (PONV) aprepitant and, 603 dolasetron and, 609 granisetron and, 614 pralatrexate, , , 460 prednisone, 529 pregnancy, use of agents in, primary induction, 2 probenecid idarubicin 29 methotrexate 87 pralatrexate and, 350 procainamide procarbazine, , , 460 prochlorperazine, , 632, 635 progestational agents megestrol acetate, Proleukin. See aldesleukin ProMACE/CytaBOM regimen, 548 prostate cancer abiraterone acetate for, 6 aminoglutethimide 3 bicalutamide and, degarelix and, 149 docetaxel and, 154, 155 enzalutamide and, 168 estramustine and, 182 flutamide 09 goserelin 19 leuprolide 67 mitoxantrone 99 nilutamide and, 309 paclitaxel and, 323 sipuleucel-t and, 367 proteasome inhibitor bortezomib, carfilzomib, protein synthesis inhibitor omacetaxine mepesuccinate, proton pump inhibitors methotrexate 87 vismodegib and, 439 Provenge. See sipuleucel-t PTCL. See peripheral T-cell lymphoma (PTCL) Purinethol. See 6-mercaptopurine PVB regimen, 579 Q quinidine R RAD001. See everolimus radiation therapy bleomycin and, 58 cisplatin and, 105 docetaxel and, 155 gemcitabine 17 paclitaxel and, 323 R-CHOP regimen, R-CHOP- 14 regimen, 546 refractory anemia azacitidine and, 42 Reglan. See metoclopramide regorafenib, , , 461 renal cell cancer aldesleukin and, 15 bevacizumab and, interferon-a 42 megestrol acetate 77 temsirolimus and, 386 reserpine thalidomide and, 389 retinoid bexarotene, tretinoin, retinoid X receptor (RXR), 51 Revlimid. See lenalidomide R-FCM regimen, 545 R-GemOx (salvage regimen), 549 rhabdomyosarcoma dactinomycin-d, 133 embryonal, 2 RICE (salvage regimen), 549 rifampicin ixabepilone 55 lapatinib 58 letrozole 65 rifampin bexarotene and, 52 cabozantinib and, 78 dasatinib and, 136 erlotinib and, 178 everolimus and, 192 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 nilotinib and, 306 temsirolimus and, 386 tretinoin and, 415 ritonavir

18 Rituxan. See rituximab rituximab, , 529, 552 and B-cell non-hodgkin s lymphoma, , 461 ibritumomab 25 RMPT regimen, 561 Roferon Interferon-a2b. See interferon-a romidepsin, , 553 Roswell Park schedule, high dose regimen, 500 RTOG chemoradiation regimen, RTOG/ECOG regimen, 467 Rubidomycin. See daunorubicin RVD regimen, 560 S salvage, 468 saquinavir sertraline SGN-35. See brentuximab signal transduction inhibitor axitinib, bosutinib, cabozantinib, crizotinib, dabrafenib, dasatinib, erlotinib, everolimus, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, ponatinib, regorafenib, sorafenib, sunitinib, temsirolimus, trametinib, vandetanib, vemurafenib, vismodegib, sipuleucel-t, Thioguanine. See thioguanine SKI-606. See bosutinib skin cancer. See also cutaneous T-cell lymphoma (CTCL); melanoma, malignant bleomycin and, 57 5-fluorouracil 05 small cell lung cancer carboplatin and, cisplatin and, 104 docetaxel and, 154 etoposide and, 185 etoposide phosphate and, 189 ifosfamide 33 ironotecan 51 paclitaxel and, 323 topotecan and, 399 sodium thiosulfate mechlorethamine 74 soft tissue sarcoma (STS) dacarbazine and, 130 gemcitabine 17 ifosfamide 33 sorafenib, , 514, , 461 sotalol sparfloxacin Sprycel. See dasatinib squamous cell carcinomas bleomycin and, 57 St. John s Wort bortezomib and, 62 cabozantinib and, 78 dasatinib and, 136 erlotinib and, everolimus and, 192 exemestane and, 196 gefitinib 13 imatinib 38 ironotecan 51 ixabepilone 55 lapatinib 58 letrozole 65 nilotinib and, 306 temsirolimus and, 386 Stanford regimen, Stanford V regimen, 541 stem cell transplant busulfan with in, 71 carboplatin dose during, 87 steroidal aromatase inactivator exemestane, Index 657

19 658 Index steroids melphalan 80 mitotane 96 streptozocin and, 372 STI571. See imatinib Stivarga. See regorafenib streptozocin, , 461 Streptozotocin. See streptozocin STS. See soft tissue sarcoma (STS) SU See sunitinib substance P/NK1 receptor antagonist aprepitant, substituted benzamide metoclopramide, sulfamethoxazole pralatrexate and, 350 sulfinpyrazone idarubicin 29 sunitinib, , 490, , 461 Sutent. See sunitinib Synribo. See omacetaxine mepesuccinate T TAC regimen, Tafinlar. See dabrafenib T-ALL. See T-cell acute lymphoblastic leukemia (T-ALL) tamoxifen, , 480, 486 adjuvant treatment to local treatment modalities, 3 455, 461 Tarceva. See erlotinib Targretin. See bexarotene Tasigna. See nilotinib taxanes albumin-bound paclitaxel, cabazitaxel, docetaxel, paclitaxel, trastuzumab and, 412 Taxol. See paclitaxel Taxotere. See docetaxel T-cell acute lymphoblastic leukemia (T-ALL) nelarabine and, 303 T-cell lymphoblastic lymphoma (T-LBL) nelarabine and, 303 T-cell prolymphocytic leukemia alemtuzumab and, 18 TCH regimen, 479, 484 TC regimen, 476 telithromycin Temodar. See temozolomide temozolomide, , 475, 554 dialysis guidelines, , 461 temsirolimus, dialysis guidelines, teratogenic potential, agents, terfenadine testicular cancer bleomycin and, cisplatin and, 104, 105 etoposide and, 185 etoposide phosphate and, 189 ifosfamide 33 thalidomide, , , 461 Thalomid. See thalidomide thiazide diuretics toremifene and, 402 thiethylperazine, 632 thioguanine, , 461 Thioplex. See thiotepa thioridazine thiotepa, , 461 thrombocytosis hydroxyurea 22 thymidine floxuridine and, fluorouracil 06 methotrexate 87 pemetrexed and, 336 pralatrexate and, 350 thymoma regimens, thyroid cancer cabozantinib and, 78 regimens, ticlopidine TIC regimen, 515 TIP (salvage regimen), 580 TIP regimen, 515 T-LBL. See T-cell lymphoblastic lymphoma (T-LBL) topoisomerase II inhibitor etoposide, etoposide phosphate,

20 topoisomerase I inhibitor ironotecan, topotecan, topotecan, , 493, 507, , 461 toremifene, , 486 Torisel. See temsirolimus tositumomab, TPF induction followed by carboplatin 1 radiation therapy, TPF regimen, 515 trametinib, , 461 trastuzumab, , , 461 doxorubicin and, 160 pertuzumab and, 339 Treanda. See bendamustine tretinoin, , 461 tricyclic antidepressants procarbazine and, 353 Triethylenethiophosphoramide. See thiotepa trimethroprim pralatrexate and, 350 trimetrexate 5-fluorouracil 06 Trisenox. See arsenic trioxide (As 2 O 3 ) troleandomycin trophoblastic neoplasms cisplatin and, 104 Tykerb. See lapatinib U unclassified therapeutic agent lenalidomide, pomalidomide, thalidomide, V VAB-6 regimen, 579 VAD regimen, 559 vandetanib, VCR. See vincristine Vectibix. See panitumumab VeIP (salvage regimen), Velban. See vinblastine Velcade. See bortezomib vemurafenib, VePesid. See etoposide verapamil everolimus and, 193 ixabepilone 55 tretinoin and, 415 vermurafenib dialysis guidelines, 464 Vesanoid. See tretinoin Vidaza. See azacitidine vinblastine, dialysis guidelines, , 461 vinca alkaloid vinblastine, vincristine, vinorelbine, vincristine, asparaginase and, , 461 vinorelbine, , 487, 518, , 461 VIP (salvage regimen), 580 VIP regimen, 581 vismodegib, vismodegih, 469 vistonuridine (PN401 ) floxuridine and, fluorouracil 06 vitamin A supplements tretinoin and, 415 voriconazole vorinostat, , 461 Votrient. See pazopanib VP-16. See etoposide VP regimen, 517 W Waldenstrom s macroglobulinemia chlorambucil and, 101 warfarin bicalutamide and, 55 capecitabine and, 83 erlotinib and, 179 etoposide and, 185 etoposide phosphate and, 189 flutamide 09 gefitinib 13 ifosfamide 34 imatinib and, lapatinib 58 letrozole 65 methotrexate and, 287 mitotane 96 nilutamide and, 309 tamoxifen and, 379 toremifene and, 402 vemurafenib and, 423 vorinostat and, 442 Index 659

21 Wilms tumor adjuvant treatment to local treatment modalities, 3 dactinomycin-d, 133 primary induction X Xalkori. See crizotinib XELIRI regimen, Xeloda. See capecitabine XELOX 1 bevacizumab regimen, 501 XELOX 1 radiation therapy, 468, XELOX regimen, 82, 496, 499 XP 1 trastuzumab regimen, 512 Xtandi. See enzalutamide Y Yervoy. See ipilimumab Z Zaltrap. S ee ziv-aflibercept Zanosar. See streptozocin ZD1839. See gefitinib Zelboraf. See vemurafenib Zevalin. See ibritumomab ziv-aflibercept, Zofran. See ondansetron Zoladex. See goserelin Zolinza. See vorinostat Zytiga. See abiraterone acetate 660 Index

22 Index 661

23 662 Index

24 Index 663

25 664 Index